Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC36 + ASC35
- Development stage
- Unknown
- Lead developer
- Ascletis Pharma
- Modality
- Peptides
- Administration
- Oral, Subcutaneous
01
Overview
ASC36 + ASC35 (also known as ASC36_35FDC) is an investigational, once-monthly subcutaneous fixed-dose co-formulation developed by Ascletis Pharma for the treatment of obesity and chronic weight management. It combines two peptide agonists discovered using Ascletis' AI-assisted structure-based drug discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies: ASC36, a next-generation amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist. Together, the combination acts on three targets: the amylin receptor, GLP-1R, and GIPR. The co-formulation utilizes a Self-Assembling Lipid Depot (SALD) formulation to enable extended dosing. In preclinical studies, ASC36 + ASC35 demonstrated superior weight loss compared to co-administered eloralintide and tirzepatide. It is currently in Phase I clinical development in the United States.
- Other names
- ASC36 + ASC35ASC36_35 co-formulation
02
Targets
CALCR (Calcitonin receptor)GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)AMY receptor (Calcitonin receptor (with ramps))
Beyond the preview
Go deeper on ASC36 + ASC35.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC36 + ASC35.